Related Experiment Video
Updated: Feb 26, 2026

11:24
Stem Cell Transplantation Strategies for the Restoration of Cognitive Dysfunction Caused by Cranial Radiotherapy
Published on: October 18, 2011
15.2K
Left hippocampus sparing whole brain radiotherapy (WBRT): A planning study
Tomas Kazda1,2, Miroslav Vrzal1,2, Tomas Prochazka1,2
1Department of Radiation Oncology, Faculty of Medicine, Masaryk University, Kamenice 5, 625 00 Brno, Czech Republic.
Summary
Unilateral sparing of the left hippocampus during whole brain radiotherapy (WBRT) shows promise for reducing cognitive decline. This planning study found left hippocampus sparing radiotherapy (LHA-WBRT) plans could improve target coverage and decrease hippocampal dose.
Area of Science:
- Radiation Oncology
- Neuro-oncology
- Cognitive Neuroscience
Background:
- Whole brain radiotherapy (WBRT) can lead to cognitive decline, particularly affecting verbal memory.
- Bilateral hippocampus avoidance (HA-WBRT) is investigated to mitigate these effects.
- Unilateral sparing of the dominant (left) hippocampus is a potential alternative strategy.
Purpose of the Study:
- To perform a dosimetrical comparison between HA-WBRT and left hippocampus sparing radiotherapy (LHA-WBRT) plans.
- To evaluate the feasibility of LHA-WBRT in maintaining target coverage and sparing the left hippocampus.
Main Methods:
- HA-WBRT plans for 10 patients were created based on the RTOG 0933 trial protocol.
- Two types of LHA-WBRT plans were generated: "BEST PTV" (maintaining left hippocampus dosimetry) and "BEST LH" (maintaining overall PTV dosimetry).
- Dosimetric parameters including conformity index, homogeneity index, and dose to critical structures were analyzed.
Main Results:
- All HA-WBRT plans met RTOG 0933 criteria.
- LHA-WBRT plans demonstrated improved homogeneity index (31.2% reduction) and reduced optic pathway dose.
- The "BEST LH" LHA-WBRT plans significantly reduced the mean dose to the left hippocampus (D100% by 11.2%, Dmax by 10.9%).
Conclusions:
- LHA-WBRT plans offer potential for improved target coverage and further dose reduction to the spared left hippocampus.
- Further clinical trials are necessary to determine the clinical significance of the observed dose reductions in the left hippocampus.

